Your browser is no longer supported. Please, upgrade your browser.
Settings
GTXI GTx, Inc. daily Stock Chart
GTXI [NASD]
GTx, Inc.
Index- P/E- EPS (ttm)-1.29 Insider Own17.70% Shs Outstand24.76M Perf Week-2.91%
Market Cap24.76M Forward P/E- EPS next Y-1.11 Insider Trans0.00% Shs Float10.46M Perf Month-11.50%
Income-30.70M PEG- EPS next Q-0.24 Inst Own25.40% Short Float14.31% Perf Quarter-3.85%
Sales- P/S- EPS this Y5.70% Inst Trans-10.82% Short Ratio1.99 Perf Half Y-29.58%
Book/sh0.87 P/B1.15 EPS next Y-14.40% ROA-86.40% Target Price1.50 Perf Year-94.71%
Cash/sh0.86 P/C1.17 EPS next 5Y0.00% ROE-104.20% 52W Range0.74 - 25.60 Perf YTD28.21%
Dividend- P/FCF- EPS past 5Y24.40% ROI- 52W High-96.09% Beta2.48
Dividend %- Quick Ratio12.40 Sales past 5Y- Gross Margin- 52W Low35.14% ATR0.06
Employees21 Current Ratio12.40 Sales Q/Q- Oper. Margin- RSI (14)36.03 Volatility5.69% 6.02%
OptionableYes Debt/Eq0.00 EPS Q/Q60.90% Profit Margin- Rel Volume0.10 Prev Close0.99
ShortableYes LT Debt/Eq0.00 EarningsMay 28 BMO Payout- Avg Volume753.61K Price1.00
Recom3.00 SMA20-8.32% SMA50-14.41% SMA200-77.11% Volume78,714 Change1.52%
Mar-05-18Reiterated Stifel Buy $16 → $45
Nov-21-17Initiated Robert W. Baird Outperform $17
Nov-09-17Initiated Stifel Buy $16
Dec-09-16Reiterated Jefferies Hold $10 → $7
Apr-05-13Initiated Stifel Buy $7
Oct-14-11Initiated Rodman & Renshaw Mkt Outperform $7
Jul-20-11Initiated Wedbush Outperform $13
Oct-27-10Upgrade Rodman & Renshaw Mkt Underperform → Mkt Perform
May-26-10Reiterated Rodman & Renshaw Mkt Underperform $1.75 → $1.25
Mar-17-10Downgrade Rodman & Renshaw Mkt Perform → Mkt Underperform $1.75
Jan-26-09Reiterated Leerink Swann Mkt Perform $18 → $10
Jan-22-09Downgrade Rodman & Renshaw Mkt Outperform → Mkt Perform
May-23-08Downgrade Cowen & Co Outperform → Neutral
Mar-25-08Initiated Rodman & Renshaw Mkt Outperform $22
Nov-07-07Reiterated Lazard Capital Buy $28 → $31
Nov-06-07Reiterated Broadpoint Capital Buy $26 → $29
Oct-11-07Initiated Wachovia Outperform
Sep-13-07Initiated First Albany Buy $26
May-10-07Initiated Citigroup Hold $24
Apr-30-07Downgrade Leerink Swann Outperform → Mkt Perform
Apr-30-19 11:00PM  Rigrodsky & Long, P.A. Files Class Action Suit Against GTx, Inc. GlobeNewswire
Apr-15-19 03:32PM  GTx (GTXI) Merger Class Action Lawsuit: Halper Sadeh LLP Announces Filing of Shareholder Class Action Lawsuit Against GTx, Inc. Concerning its Proposed Merger With Oncternal Therapeutics, Inc. GTXI GlobeNewswire
Apr-01-19 07:07PM  INVESTOR ALERT: Monteverde & Associates PC is Investigating the Recently Announced Acquisition PR Newswire
Mar-22-19 02:14PM  Lifshitz & Miller LLP Announces Investigation of Amarin Corporation plc, Clementia Pharmaceuticals Inc., CVS Health Corporation, Diplomat Pharmacy, Inc., GTx, Inc., Multi-Color Corporation, Osiris Therapeutics, Inc., and The Kraft Heinz Company PR Newswire
06:00AM  Editorial: GTx's fall is not a failure American City Business Journals
Mar-20-19 09:00PM  Bragar Eagel & Squire, P.C. Reminds Investors that it is Investigating the Boards of Directors of Clementia, Multi-Color, and GTx on Behalf of Stockholders and Encourages Investors to Contact the Firm GlobeNewswire
Mar-13-19 08:10AM  GTx's legacy: The once-promising pillar of Memphis' 'biotech core' American City Business Journals
Mar-11-19 02:42PM  GTX INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Merger of GTx, Inc. - GTXI PR Newswire -12.86%
Mar-07-19 06:05PM  GTX, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of Merger Business Wire +67.72%
10:33AM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Regarding Whether the Sale of GTx, Inc. to Oncternal Therapeutics, Inc. is Fair to Shareholders GlobeNewswire
09:40AM  Watch These Four Healthcare Stocks Set The Standard on Thursday ACCESSWIRE
08:10AM  GTx merges with biotech firm, new HQ to be based in San Diego American City Business Journals
07:00AM  GTx and Oncternal Therapeutics Enter into Definitive Merger Agreement to Create Nasdaq-Listed Clinical-Stage Company Developing a Diverse Pipeline of Novel Cancer Therapies Business Wire
Feb-13-19 12:28PM  CEOs of ServiceMaster, First Horizon, AutoZone react to FedEx Logistics move American City Business Journals
Feb-07-19 08:25AM  Analysis: Positioning to Benefit within Skyworks Solutions, Atmos Energy, Ellie Mae, ScanSource, REV Group, and GTx Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Nov-08-18 09:00AM  Recent Analysis Shows Automatic Data Processing, GTx, Ionis Pharmaceuticals, TriNet Group, Ternium S.A, and UNIVERSAL INSURANCE HOLDINGS INC Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
Oct-31-18 02:03AM  [$$] Spinal implants enable paraplegic patients to walk again Financial Times +5.30%
Oct-25-18 08:22AM  Zacks.com featured highlights include: Guess?, GTX, NCI, EMCOR and Mitek Zacks
Oct-24-18 07:49AM  What Overvaluation? 5 Stocks With Rising P/E Are Good Buys Zacks -7.56%
Oct-22-18 07:03AM  GTx: 3Q Earnings Snapshot Associated Press
07:00AM  GTx Reports Third Quarter 2018 Financial Results and Provides Corporate Update Business Wire
Oct-16-18 12:14PM  Who makes what: Big bucks paid to Memphis' top company execs American City Business Journals +16.77%
08:50AM  New Research Coverage Highlights Adesto Technologies, Pain Therapeutics, U.S. Global Investors, GTx, Columbus McKinnon, and Baytex Energy Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire
Oct-08-18 08:00AM  Todays Research Reports on Stocks to Watch: GTx and TrovaGene ACCESSWIRE -6.28%
Sep-24-18 08:00AM  Todays Research Reports on Stocks to Watch: GTx and Protalix BioTherapeutics ACCESSWIRE
Sep-21-18 04:38PM  Why GTx, Tilray, and United Natural Foods Slumped Today Motley Fool -92.27%
03:33PM  Here's Why GTx, Inc. Dropped Over 92% Today Motley Fool
01:35PM  Pot-Enthusiasts Beware: GTx Shows How a Hot Trend Can Reverse Bloomberg
08:39AM  GTx Inc. stock drops 94% premarket after phase 2 trial failure MarketWatch
08:00AM  GTx Announces Top-Line Results from Placebo-Controlled ASTRID Trial of Enobosarm in Women with Stress Urinary Incontinence Business Wire
Sep-18-18 08:55AM  Are Options Traders Betting on a Big Move in GTx (GTXI) Stock? Zacks
Aug-30-18 07:00AM  GTx, Inc. to Participate in the Baird 2018 Global Healthcare Conference Business Wire +14.81%
Aug-20-18 08:20AM  Recent Analysis Shows Ferroglobe, AXT, ChemoCentryx, RedHill Biopharma, GTx, and Achillion Pharmaceuticals Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
Aug-14-18 07:07AM  GTx: 2Q Earnings Snapshot Associated Press
07:00AM  GTx Provides Corporate Update and Reports Second Quarter 2018 Financial Results Business Wire
Aug-13-18 09:45AM  VKTX: Data from P2 Trial of VK2809 in 4Q18 Zacks Small Cap Research
Jun-25-18 07:00AM  GTx Added to the Russell 3000® Index Business Wire
Jun-05-18 07:40AM  Detailed Research: Economic Perspectives on First Mid-Illinois Bancshares, GTx, Ferroglobe, SunOpta, Bandwidth, and Carbonite What Drives Growth in Today's Competitive Landscape GlobeNewswire
May-31-18 07:00AM  GTx, Inc. to Participate in the Jefferies 2018 Global Healthcare Conference Business Wire
May-18-18 02:00PM  GTx Updates Phase 2 Enobosarm Clinical Trial Results in Stress Urinary Incontinence at 2018 AUA Annual Meeting Business Wire
May-16-18 10:59AM  Does GTx Incs (NASDAQ:GTXI) -71.74% Earnings Drop Reflect A Longer Term Trend? Simply Wall St. +10.69%
May-15-18 07:04AM  GTx: 1Q Earnings Snapshot Associated Press
07:00AM  GTx Provides Corporate Update and Reports First Quarter 2018 Financial Results Business Wire
May-13-18 10:06AM  The Week Ahead In Biotech: PDUFA Dates, Earnings, IPOs And More Benzinga
Apr-16-18 07:00AM  GTx to Present Phase 2 Enobosarm Clinical Trial Results in Stress Urinary Incontinence at a Podium Presentation at 2018 AUA Annual Meeting Business Wire
Apr-13-18 08:15AM  Research Report Identifies Third Point Reinsurance, GTx, pdvWireless, ACM Research, Reading International, and Canadian National Railway with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
Apr-11-18 07:10AM  Blog Exposure - GTx Completed Patient Enrollment Several Months Ahead in the Phase-2 Clinical Trial of Enobosarm in SUI ACCESSWIRE
Apr-09-18 07:00AM  GTx Announces Early Completion of Patient Enrollment in the ASTRID Trial, a Phase 2 Clinical Trial of Enobosarm in Stress Urinary Incontinence Business Wire
Mar-15-18 08:00AM  Report: Developing Opportunities within Odonate Therapeutics, Greenlight Reinsurance, Landmark Infrastructure Partners LP, GTx, First Mid-Illinois Bancshares, and iClick Interactive Asia Group Future Expectations, Projections Moving into 2018 GlobeNewswire
Mar-12-18 04:21PM  GTx reports 4Q loss Associated Press
04:05PM  GTx Provides Corporate Update and Reports Fourth Quarter and Full Year 2017 Financial Results Business Wire
Mar-05-18 04:40PM  Why Square, CF Industries Holdings, and GTx Jumped Today Motley Fool +38.31%
12:39PM  GTx shares surge 30% on incontinence trial results MarketWatch
10:43AM  GTx, Inc. (GTXI) Soars 25% in Light of Encouraging Data in SUI SmarterAnalyst
07:00AM  GTx Announced New Data Demonstrating Enobosarms Potential to Treat Stress Urinary Incontinence at SUFU 2018 Business Wire
Feb-22-18 04:00PM  GTx Phase 2 Enobosarm Clinical Trial Results in Stress Urinary Incontinence Accepted for Podium Presentation at SUFU Business Wire
Jan-26-18 02:30PM  Chairwoman of the board? Memphis public companies talk top-level gender diversity American City Business Journals
Nov-16-17 05:14AM  GTx reports 3Q loss Associated Press -15.98%
Nov-14-17 04:05PM  GTx Provides Corporate Update and Reports Third Quarter 2017 Financial Results Business Wire
Nov-08-17 07:30AM  GTx, Inc. to Participate in the Stifel 2017 Healthcare Conference Business Wire -7.97%
Sep-29-17 04:05PM  GTx Announces Closing of $48.5 Million Private Placement Business Wire
Sep-26-17 07:30AM  GTx Announces $48.5 Million Private Placement Business Wire
Sep-25-17 05:50PM  GTx Announces Webcast of Corporate Presentation at the 2017 Cantor Fitzgerald Global Healthcare Conference Business Wire
Sep-21-17 04:05PM  GTx to Host Key Opinion Leader Luncheon on the Topic of Stress Urinary Incontinence on September 28th in New York City Business Wire
Sep-14-17 05:50PM  GTx's (GTXI) Enobosarm Positive in Phase II, Shares Down Zacks
Sep-13-17 07:00AM  GTx Announces Positive Results from Enobosarm Phase 2 Proof-of-Concept Clinical Trial in Women with Stress Urinary Incontinence Business Wire -8.91%
Aug-14-17 10:09PM  GTx reports 2Q loss Associated Press
07:00AM  GTx Provides Corporate Update and Reports Second Quarter 2017 Financial Results Business Wire
Jul-12-17 01:42PM  GTx Discusses Key Goals with WSA Marketwired
Jun-13-17 10:14AM  GTx's (GTXI) Enobosarm Positive in Phase II Study; Shares Up Zacks -21.63%
08:00AM  Today's Research Reports on Stocks to Watch: Xbiotech and GTx Accesswire
Jun-12-17 07:00AM  GTx Announces Positive Preliminary Results from Ongoing Phase 2 Proof-of-Concept Clinical Trial in Women with Stress Urinary Incontinence Business Wire +99.03%
May-15-17 07:10AM  GTx reports 1Q loss Associated Press
07:00AM  GTx Provides Corporate Update and Reports First Quarter 2017 Financial Results Business Wire
May-11-17 07:00AM  GTx Announces Acceptance of an Abstract on Preliminary Results from Phase 2 Clinical Trial in Women with Stress Urinary Incontinence at the International Continence Society Annual Meeting Business Wire
May-03-17 07:00AM  GTx Announces Results from Preclinical Studies of SARMs in Duchenne Muscular Dystrophy Models Published in Human Molecular Genetics Business Wire
Mar-30-17 01:04PM  GTX INC /DE/ Financials
Mar-15-17 07:40AM  GTX INC /DE/ Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
07:12AM  GTx reports 4Q loss Associated Press
07:07AM  Q4 2016 GTX Inc Earnings Release - Before Market Open
07:00AM  GTx Provides Corporate Update and Reports Fourth Quarter and Year-End 2016 Financial Results Business Wire
Mar-07-17 07:00AM  GTx, Inc. to Report Fourth Quarter and Full Year 2016 Financial Results on March 15, 2017 Business Wire
Jan-09-17 04:31PM  GTX INC /DE/ Files SEC form 8-K, Change in Directors or Principal Officers
Dec-21-16 12:16PM  GTX INC /DE/ Files SEC form 8-K, Other Events
Dec-16-16 05:24AM  Is GTx, Inc. (GTXI) A Good Stock To Buy? Insider Monkey
05:24AM  Is GTx, Inc. (GTXI) A Good Stock To Buy? at Insider Monkey
Dec-08-16 03:13PM  GTX INC /DE/ Files SEC form 8-K, Other Events, Financial Statements and Exhibits
07:00AM  GTx Reports Results from Ongoing Enobosarm Phase 2 Clinical Trial in ER+/AR+ Breast Cancer Business Wire
Dec-06-16 10:20AM  GTx Declares 1-For-10 Reverse Stock Split (GTXI) Investopedia
10:20AM  GTx Declares 1-For-10 Reverse Stock Split (GTXI) at Investopedia
Dec-05-16 04:07PM  GTX INC /DE/ Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statement
08:34AM  GTx, Inc. Announces 1-for-10 Reverse Stock Split Business Wire
Dec-01-16 08:38AM  GTx, Inc. :GTXI-US: Earnings Analysis: Q3, 2016 By the Numbers : December 1, 2016 Capital Cube
08:38AM  GTx, Inc. :GTXI-US: Earnings Analysis: Q3, 2016 By the Numbers : December 1, 2016
Nov-28-16 10:25AM  GTX INC /DE/ Files SEC form 8-K, Other Events, Financial Statements and Exhibits
07:00AM  Enobosarm Meets Pre-Specified Primary Efficacy Endpoint in Ongoing Phase 2 Clinical Trial in ER+/AR+ Breast Cancer Business Wire
Nov-23-16 07:00AM  GTx Announces Webcast of Corporate Presentation at the 28th Annual Piper Jaffray Healthcare Conference Business Wire
Nov-17-16 02:31PM  Heres What To Look For When The Real GTx, Inc. (GTXI) Data Hits at Insider Monkey
08:15AM  Blog Coverage GTx Inc. Enobosarm Achieves Stage 1 Milestone Accesswire
Nov-16-16 07:31AM  GTX INC /DE/ Files SEC form 8-K, Other Events, Financial Statements and Exhibits
GTx, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of medicines for the treatment of stress urinary incontinence (SUI) and prostate cancer. It develops selective androgen receptor modulators (SARMs) for the treatment of breast cancer, SUI, and Duchenne muscular dystrophy; and selective androgen receptor degraders to treat progressive castration-resistant prostate cancer. The company's SARM product candidate is the enobosarm GTx-024, a Phase II proof-of-concept clinical trial for patients with androgen receptor (AR) positive triple-negative breast cancer; and estrogen receptor positive and AR positive advanced breast cancer, as well as postmenopausal women with SUI. GTx, Inc. was founded in 1997 and is headquartered in Memphis, Tennessee.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Wills Robert JamesExecutive ChairmanJun 26Buy16.755,00083,750137,344Jun 26 11:21 AM
DOGGRELL HENRY PATTONVP, Chief Legal OfficerJun 20Sale19.017,351139,70843,630Jun 22 05:16 PM
Shackelford Jason TPrin Fin. & Acct. OfficerJun 20Sale19.019,279176,35019,453Jun 22 05:15 PM